Resumo

APARICIO HERNANDEZ, R; GARCIA LUQUE, A; PRATS OLIVAN, P  e  SANCHEZ LOPEZ, P. Possitive assesment of drugs: September, October and November 2018. Sanid. Mil. [online]. 2019, vol.75, n.1, pp.19-26. ISSN 1887-8571.  https://dx.doi.org/10.4321/s1887-85712019000100004.

The drugs assessed by the Spanish Agency for Medicines and Health Products or European Medicines Agency made public in September, October and November of 2018, and considered of interest to the healthcare profesional, are reviewed. These are positive technical reports prior to the authorization and placing on the market of the product.

Palavras-chave : Antígenos de superficie inactivados del virus de la gripe, hemaglutinina y neuraminidasa (Flucelvax tetra^®); Apalutamida (Erleada^®); Brigatinib (Alunbrig^®); Damoctocog alfa pegol (Jivi^®); Doravirina (Pifeltro^®); Doravirina, Lamivudina, Tenofovir disoproxilo (Delstrigo^®); Galcanezumab (Emgality^®); Glicopirronio/Formoterol fumarato dihidrato (Bevespi aerosphere^®); Macimorelina (Macimorelin aeterna zentaris^®); Meropenem/Vaborbactam (Vabomere^®); Ladanelumab (Takhzyro^®); Mexiletina (Namuscla^®); Mogamulizumab (Poteligeo^®); Paclitaxel (Apealea^®); Pegfilgrastim (Fulphila^®; Pelmeg^®; Ziextenzo^®); Trastuzumab (Ogivri^®); Vacuna viva atenuada tetravalente del dengue (Dengvaxia^®); Voretigene neparvovec (Luxturna^®).

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )